Current evidence for immune checkpoint inhibition in advanced hepatocellular carcinoma
Name:
37754543.pdf
Size:
660.6Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UKIssue Date
2023
Metadata
Show full item recordAbstract
The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint inhibition (ICI), either combined with anti-angiogenic therapy or dual ICI, as preferred first-line therapy for eligible patients with aHCC. Numerous other combination regimens involving ICI are under investigation with the aim of improving the tumour response and survival of patients with all stages of HCC. This review will explore the current evidence for ICI in patients with advanced HCC and discuss future directions, including the unmet clinical need for predictive biomarkers to facilitate patient selection, the effects of cirrhosis aetiology on response to ICI, and the safety of its use in patients with impaired liver function.Citation
Foy V, McNamara MG, Valle JW, Lamarca A, Edeline J, Hubner RA. Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma. Current oncology (Toronto, Ont). 2023 Sep 21;30(9):8665-85. PubMed PMID: 37754543. Pubmed Central PMCID: PMC10529518. Epub 2023/09/27. eng.Journal
Current OncologyDOI
10.3390/curroncol30090628PubMed ID
37754543Additional Links
https://dx.doi.org/10.3390/curroncol30090628Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.3390/curroncol30090628
Scopus Count
Collections
Related articles
- The Treatment Landscape of Advanced Hepatocellular Carcinoma.
- Authors: Wong KM, King GG, Harris WP
- Issue date: 2022 Jul
- Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
- Authors: Zheng J, Shao M, Yang W, Ren J, Chen X, Yang H
- Issue date: 2022 Nov
- Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
- Authors: Rizzo A, Brandi G
- Issue date: 2021
- PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects.
- Authors: D'Alessio A, Rimassa L, Cortellini A, Pinato DJ
- Issue date: 2021
- Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
- Authors: Li Y, Liang X, Li H, Chen X
- Issue date: 2023 Sep 20